Prime Medicine Inc. (PRME)
PRME trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1894562/000162828026013569/0001628280-26-013569-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PRME on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001894562 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.6M |
| Net income | -$201.1M |
| Operating income | -$208.3M |
| Net margin | -4342.4% |
| Operating margin | -4498.1% |
| Revenue growth | +55.3% |
| Cash | $63.0M |
| Total assets | $342.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 164.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued." | 10-Q 2026-11-12 |
| Cash and burn | $54.9M cash; operating cash flow -$39.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 181,921,405 (2026-10-31); 180,510,658 a year earlier; 97,324,301 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-11-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $4.2M | -$39.0M | -$36.7M | $54.9M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$42.1M | -$41.0M | $47.5M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$49.1M | -$42.7M | $64.1M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | $838K | -$46.1M | -$37.3M | $63.0M | No debt tags | $4.6M | 10-K 2026-03-03 |
| Q3 2025 2025-09-30 | $1.2M | -$50.6M | -$35.0M | $71.4M | No debt tags | $6.0M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $1.1M | -$52.6M | -$41.4M | $53.8M | No debt tags | $5.0M | 10-Q 2025-08-07 |
| Q1 2025 2025-03-31 | $1.5M | -$51.9M | -$48.9M | $91.9M | No debt tags | $3.8M | 10-Q 2025-05-08 |
| Q4 2024 2024-12-31 | $2.2M | -$42.3M | $16.2M | $182.5M | No debt tags | $3.0M | 10-K 2026-03-03 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-12 |
| Latest annual report | 10-K | 2026-03-03 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 306 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.2% |
| 1 month | +28.6% |
| 3 months | +34.7% |
| Year to date | +23.1% |
| 1 year | +28.2% |
| From 52-week high | -20.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AURA | Aura Biosciences Inc. | $7.22 | +1.55% | $751.4M |
| GLUE | Monte Rosa Therapeutics Inc. | $9.16 | -2.24% | $782.7M |
| SLDB | Solid Biosciences Inc. | $6.48 | -5.26% | $723.2M |
| MGTX | MeiraGTx Holdings plc | $8.74 | -4.79% | $854.2M |
| ATTO | Attovia Therapeutics Inc. | $14.72 | -2.68% | $673.1M |
| DBVT | DBV Technologies S.A. | $10.27 | -6.76% | $645.8M |
| BBTX | Bambusa Therapeutics Inc. | $15.98 | -0.68% | $645.4M |
| FDMT | 4D Molecular Therapeutics Inc. | $11.29 | -7.69% | $636.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier